Hepion reported no revenue for FY 2025 and posted a net loss of USD 8.28 million, narrowing 37% year over year. Loss from operations was USD 4.16 million, narrowing 78%, as research and development expense fell 96% to USD 0.45 million due mainly to lower clinical trial and drug development spending after the ASCEND-NASH trial wind-down, partially offset by purchased in-process R&D tied to the New Day asset acquisition. General and administrative expense declined 56% to USD 3.32 million, driven primarily by lower employee compensation, stock-based compensation, consulting, professional fees and rent. Cash and working capital were USD 1.8 million and USD 2.8 million at Dec. 31, 2025, compared with a working capital deficit of USD 1.5 million a year earlier. The company said it concluded there is substantial doubt about its ability to continue as a going concern without additional capital, and noted it in-licensed diagnostic tests from New Day, including CE-marked celiac, respiratory multiplex and H. pylori tests eligible for sale in the EU and certain other markets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-009755), on March 12, 2026, and is solely responsible for the information contained therein.
Comments